These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 37131012)

  • 41. The impact of anti-TNFα agents on weight-related changes: new insights from a real-world pharmacovigilance study using the FDA adverse event reporting system (FAERS) database.
    Mazhar F; Battini V; Gringeri M; Pozzi M; Mosini G; Marran AMN; Akram S; van Manen RP; Radice S; Clementi E; Carnovale C
    Expert Opin Biol Ther; 2021 Sep; 21(9):1281-1290. PubMed ID: 34191656
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Quantifying the Severity of Adverse Drug Reactions Using Social Media: Network Analysis.
    Lavertu A; Hamamsy T; Altman RB
    J Med Internet Res; 2021 Oct; 23(10):e27714. PubMed ID: 34673524
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Drug Safety Monitoring in Children: Performance of Signal Detection Algorithms and Impact of Age Stratification.
    Osokogu OU; Dodd C; Pacurariu A; Kaguelidou F; Weibel D; Sturkenboom MC
    Drug Saf; 2016 Sep; 39(9):873-81. PubMed ID: 27255487
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A Data-Driven Reference Standard for Adverse Drug Reaction (RS-ADR) Signal Assessment: Development and Validation.
    Lee S; Lee JH; Kim GJ; Kim JY; Shin H; Ko I; Choe S; Kim JH
    J Med Internet Res; 2022 Oct; 24(10):e35464. PubMed ID: 36201386
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Exploration of statistical shrinkage parameters of disproportionality methods in spontaneous reporting system of China.
    Wang J; Ye XF; Guo XJ; Zhu TT; Qi N; Hou YF; Zhang TY; Shi WT; Wei X; Liu YZ; Wu GZ; He J
    Pharmacoepidemiol Drug Saf; 2015 Sep; 24(9):962-70. PubMed ID: 26095121
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Assessment of acute kidney injury related to small-molecule protein kinase inhibitors using the FDA adverse event reporting system.
    Fan Q; Ma J; Zhang B; Li Q; Liu F; Zhao B
    Cancer Chemother Pharmacol; 2020 Nov; 86(5):655-662. PubMed ID: 33001273
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Toxicity signals associated with secukinumab: A pharmacovigilance study based on the United States Food and Drug Administration Adverse Event Reporting System database.
    Zheng Y; Guo X; Chen C; Chi L; Guo Z; Liang J; Wei L; Chen X; Ye X; He J
    Br J Clin Pharmacol; 2023 Feb; 89(2):865-873. PubMed ID: 36106653
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Vaccine-based subgroup analysis in VigiBase: effect on sensitivity in paediatric signal detection.
    de Bie S; Verhamme KM; Straus SM; Stricker BH; Sturkenboom MC
    Drug Saf; 2012 Apr; 35(4):335-46. PubMed ID: 22435344
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Complementing the US Food and Drug Administration Adverse Event Reporting System With Adverse Drug Reaction Reporting From Social Media: Comparative Analysis.
    Zhou Z; Hultgren KE
    JMIR Public Health Surveill; 2020 Sep; 6(3):e19266. PubMed ID: 32996889
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Novel Adverse Events of Iloperidone: A Disproportionality Analysis in US Food and Drug Administration Adverse Event Reporting System (FAERS) Database.
    Subeesh V; Maheswari E; Singh H; Beulah TE; Swaroop AM
    Curr Drug Saf; 2019; 14(1):21-26. PubMed ID: 30362421
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Analysis of pharmacovigilance databases for spontaneous reports of adverse drug reactions related to substandard and falsified medical products: A descriptive study.
    Pozsgai K; Szűcs G; Kőnig-Péter A; Balázs O; Vajda P; Botz L; Vida RG
    Front Pharmacol; 2022; 13():964399. PubMed ID: 36147337
    [No Abstract]   [Full Text] [Related]  

  • 52. Methods to Compare Adverse Events in Twitter to FAERS, Drug Information Databases, and Systematic Reviews: Proof of Concept with Adalimumab.
    Smith K; Golder S; Sarker A; Loke Y; O'Connor K; Gonzalez-Hernandez G
    Drug Saf; 2018 Dec; 41(12):1397-1410. PubMed ID: 30167992
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Data mining for adverse drug reaction signals of daptomycin based on real-world data: a disproportionality analysis of the US Food and Drug Administration adverse event reporting system.
    Chen JJ; Huo XC; Wang SX; Wang F; Zhao Q
    Int J Clin Pharm; 2022 Dec; 44(6):1351-1360. PubMed ID: 36178607
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A Pharmacovigilance Study of Adverse Drug Reactions Reported for Cardiovascular Disease Medications Approved Between 2012 and 2017 in the United States Food and Drug Administration Adverse Event Reporting System (FAERS) Database.
    Patel NM; Stottlemyer BA; Gray MP; Boyce RD; Kane-Gill SL
    Cardiovasc Drugs Ther; 2022 Apr; 36(2):309-322. PubMed ID: 33599896
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Profiling cumulative proportional reporting ratios of drug-induced liver injury in the FDA Adverse Event Reporting System (FAERS) database.
    Brinker AD; Lyndly J; Tonning J; Moeny D; Levine JG; Avigan MI
    Drug Saf; 2013 Dec; 36(12):1169-78. PubMed ID: 24178291
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Adverse Drug Reaction Risk Measures: A Comparison of Estimates from Drug Surveillance and Randomised Trials.
    Beau-Lejdstrom R; Crook S; Spanu A; Yu T; Puhan MA
    Pharmaceut Med; 2019 Aug; 33(4):331-339. PubMed ID: 31933187
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Use of Disproportionality Analysis to Identify Previously Unknown Drug-Associated Causes of Cardiac Arrhythmias Using the Food and Drug Administration Adverse Event Reporting System (FAERS) Database.
    Moreland-Head LN; Coons JC; Seybert AL; Gray MP; Kane-Gill SL
    J Cardiovasc Pharmacol Ther; 2021 Jul; 26(4):341-348. PubMed ID: 33403858
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effect of database profile variation on drug safety assessment: an analysis of spontaneous adverse event reports of Japanese cases.
    Nomura K; Takahashi K; Hinomura Y; Kawaguchi G; Matsushita Y; Marui H; Anzai T; Hashiguchi M; Mochizuki M
    Drug Des Devel Ther; 2015; 9():3031-41. PubMed ID: 26109846
    [TBL] [Abstract][Full Text] [Related]  

  • 59. How do patients contribute to signal detection? : A retrospective analysis of spontaneous reporting of adverse drug reactions in the UK's Yellow Card Scheme.
    Hazell L; Cornelius V; Hannaford P; Shakir S; Avery AJ;
    Drug Saf; 2013 Mar; 36(3):199-206. PubMed ID: 23444232
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Lessons learned on the design and the conduct of Post-Authorization Safety Studies: review of 3 years of PRAC oversight.
    Engel P; Almas MF; De Bruin ML; Starzyk K; Blackburn S; Dreyer NA
    Br J Clin Pharmacol; 2017 Apr; 83(4):884-893. PubMed ID: 27780289
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.